AARD
Aardvark Therapeutics, Inc. Common Stock
NASDAQ · Healthcare · Biotechnology · US
$5.38
−6.11%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Expenses | |||||
| R&D Expense | 55.1M | 48.9M | 17.4M | 4.5M | 7.2M |
| SG&A Expense | 18.9M | 13.8M | 5.3M | 2.2M | 2.7M |
| General & Admin Expense | 18.9M | 13.8M | 5.3M | 2.2M | 2.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | 117.0K | 762.0K | 1.5M |
| Total Operating Expenses | 74.0M | 62.7M | 22.8M | 7.4M | 11.4M |
| Cost and Expenses | 74.0M | 62.7M | 22.8M | 7.4M | 11.4M |
| Operating Income (EBIT) | (74.0M) | (62.7M) | (22.8M) | (7.4M) | (11.4M) |
| Non-Operating | |||||
| Interest Income | 4.1M | 5.1M | 2.4M | 1.4M | 120.0K |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 4.1M | 5.1M | 2.4M | 1.4M | 120.0K |
| Other Non-Op Income/Expense | 4.1M | 5.1M | 2.2M | 207.0K | (2.2M) |
| Non-Operating Income (excl Interest) | (4.1M) | (5.1M) | (117.0K) | (762.0K) | (489.0K) |
| EBT (Pre-Tax Income) | (69.9M) | (57.6M) | (20.6M) | (7.2M) | (13.6M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (69.9M) | (57.6M) | (20.6M) | (7.2M) | (13.6M) |
| Earnings from Cont. Ops | (69.9M) | (57.6M) | (20.6M) | (7.2M) | (13.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (69.9M) | (57.6M) | (20.6M) | (7.2M) | (13.6M) |
| Per Share | |||||
| Basic EPS | ($3.21) | ($2.64) | ($0.95) | ($0.34) | ($0.63) |
| Diluted EPS | ($3.21) | ($2.64) | ($0.95) | ($0.34) | ($0.63) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 21.8M | 21.8M | 21.7M | 21.4M | 21.4M |
| Diluted Shares Outstanding | 21.8M | 21.8M | 21.7M | 21.4M | 21.4M |
| Profitability Metrics | |||||
| EBITDA | (69.9M) | (57.6M) | (22.7M) | (6.6M) | (10.8M) |
| D&A | 31.0K | 36.0K | 16.0K | 97.0K | 110.0K |
| EBIT | (69.9M) | (57.6M) | (22.7M) | (6.7M) | (10.9M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026